Parkinson's Disease and Cognitive Impairment

Yang Yang, Bei-Sha Tang, Ji-Feng Guo, Yang Yang, Bei-Sha Tang, Ji-Feng Guo

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models of Parkinson's disease for years, it is now well recognized that Parkinson's disease is more than just a motor-deficit disorder. The majority of Parkinson's disease patients suffer from nonmotor disabilities, for instance, cognitive impairment, autonomic dysfunction, sensory dysfunction, and sleep disorder. So far, anti-PD prescriptions and surgical treatments have been mainly focusing on motor dysfunctions, leaving cognitive impairment a marginal clinical field. Within the nonmotor symptoms, cognitive impairment is one of the most common and significant aspects of Parkinson's disease, and cognitive deficits such as dysexecutive syndrome and visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, and therefore increase burdens of caregiver and medical costs. In this review, we have done a retrospective study of the recent related researches on epidemiology, clinical manifestation and diagnosis, genetics, and potential treatment of cognitive deficits in Parkinson's disease, aiming to provide a summary of cognitive impairment in Parkinson's disease and make it easy for clinicians to tackle this challenging issue in their future practice.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Litvan I., Bhatia K. P., Burn D. J., et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Movement Disorders. 2003;18(5):467–486. doi: 10.1002/mds.10459.
    1. Buter T. C., van den Hout A., Matthews F. E., Larsen J. P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022. doi: 10.1212/01.wnl.0000306632.43729.24.
    1. Hely M. A., Reid W. G. J., Adena M. A., Halliday G. M., Morris J. G. L. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837–844. doi: 10.1002/mds.21956.
    1. Aarsland D., Andersen K., Larsen J. P., Lolk A., Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology. 2003;60(3):387–392. doi: 10.1001/archneur.60.3.387.
    1. Levy G., Tang M.-X., Louis E. D., et al. The association of incident dementia with mortality in PD. Neurology. 2002;59(11):1708–1713. doi: 10.1212/01.WNL.0000036610.36834.E0.
    1. Weintraub D., Mavandadi S., Mamikonyan E., et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–455. doi: 10.1212/WNL.0b013e3181ebdd79.
    1. Sinforiani E., Banchieri L., Zucchella C., Pacchetti C., Sandrini G. Cognitive rehabilitation in Parkinson's disease. Archives of gerontology and geriatrics. Supplement. 2004;(9):387–391.
    1. París A. P., Saleta H. G., de la Cruz Crespo Maraver M., et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Movement Disorders. 2011;26(7):1251–1258. doi: 10.1002/mds.23688.
    1. Broeders M., Velseboer D. C., de Bie R., et al. Cognitive change in newly-diagnosed patients with Parkinson's disease: a 5-year follow-up study. Journal of the International Neuropsychological Society. 2013;19(6):695–708. doi: 10.1017/s1355617713000295.
    1. Pedersen K. F., Larsen J. P., Tysnes O.-B., Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurology. 2013;70(5):580–586. doi: 10.1001/jamaneurol.2013.2110.
    1. Hershey L. A., Peavy G. M. Cognitive decline in Parkinson disease: how steep and crowded is the slope? Neurology. 2015;85(15):1268–1269. doi: 10.1212/wnl.0000000000002003.
    1. Hely M. A., Morris J. G. L., Reid W. G. J., Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Movement Disorders. 2005;20(2):190–199. doi: 10.1002/mds.20324.
    1. Buter T. C., Van Den Hout A., Matthews F. E., Larsen J. P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: A 12-year Population Study. Neurology. 2008;70(13):1017–1022. doi: 10.1212/01.wnl.0000306632.43729.24.
    1. Aarsland D., Andersen K., Larsen J. P., Lolk A., Nielsen H., Kragh-Sørensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56(6):730–736. doi: 10.1212/wnl.56.6.730.
    1. Hobson P., Gallacher J., Meara J. Cross-sectional survey of Parkinson's disease and parkinsonism in a rural area of the United Kingdom. Movement Disorders. 2005;20(8):995–998. doi: 10.1002/mds.20489.
    1. Reid W. G. J., Hely M. A., Morris J. G. L., Loy C., Halliday G. M. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study) Journal of Neurology, Neurosurgery and Psychiatry. 2011;82(9):1033–1037. doi: 10.1136/jnnp.2010.232678.
    1. Pigott K., Rick J., Xie S. X., et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015;85(15):1276–1282. doi: 10.1212/WNL.0000000000002001.
    1. Aarsland D., Bronnick K., Williams-Gray C., et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069. doi: 10.1212/wnl.0b013e3181f39d0e.
    1. Bower J. H., Maraganore D. M., Peterson B. J., McDonnell S. K., Ahlskog J. E., Rocca W. A. Head trauma preceding PD: A Case-control Study. Neurology. 2003;60(10):1610–1615. doi: 10.1212/01.wnl.0000068008.78394.2c.
    1. Braak H., Braak E. Pathoanatomy of Parkinson's disease. Journal of Neurology, Supplement. 2000;247(2):3–10. doi: 10.1007/s004150050002.
    1. Di Fonzo A., Dekker M. C. J., Montagna P., et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009;72(3):240–245. doi: 10.1212/01.wnl.0000338144.10967.2b.
    1. Di Fonzo A., Rohé C. F., Ferreira J., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. 2005;365(9457):412–415. doi: 10.1016/S0140-6736(05)17829-5.
    1. Elbaz A., Bower J. H., Maraganore D. M., et al. Risk tables for parkinsonism and Parkinson's disease. Journal of Clinical Epidemiology. 2002;55(1):25–31. doi: 10.1016/S0895-4356(01)00425-5.
    1. Farrer M., Chan P., Chen R., et al. Lewy bodies and parkinsonism in families with parkin mutations. Annals of Neurology. 2001;50(3):293–300. doi: 10.1002/ana.1132.
    1. Foroud T., Uniacke S. K., Liu L., et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60(5):796–801. doi: 10.1212/01.WNL.0000049470.00180.07.
    1. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's Disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology. 2002;51(3):296–301. doi: 10.1002/ana.10113.
    1. Gilks W. P., Abou-Sleiman P. M., Gandhi S., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. The Lancet. 2005;365(9457):415–416. doi: 10.1016/s0140-6736(05)17830-1.
    1. Goldwurm S., Zini M., Mariani L., et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology. 2007;68(14):1141–1143. doi: 10.1212/01.wnl.0000254483.19854.ef.
    1. Healy D. G., Falchi M., O'Sullivan S. S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. The Lancet Neurology. 2008;7(7):583–590. doi: 10.1016/S1474-4422(08)70117-0.
    1. Hughes A. J., Ben-Shlomo Y., Daniel S. E., Lees A. J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 2001;57(10):S34–S38.
    1. Hughes A. J., Daniel S. E., Ben-Shlomo Y., Lees A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(4):861–870. doi: 10.1093/brain/awf080.
    1. Hulihan M. M., Ishihara-Paul L., Kachergus J., et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. The Lancet Neurology. 2008;7(7):591–594. doi: 10.1016/S1474-4422(08)70116-9.
    1. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher M. G., Lang A. E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. The Lancet Neurology. 2007;6(7):652–662. doi: 10.1016/s1474-4422(07)70174-6.
    1. Hicks A. A., Pétursson H., Jónsson T., et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Annals of Neurology. 2002;52(5):549–555. doi: 10.1002/ana.10324.
    1. Giovannone B., Lee E., Laviola L., Giorgino F., Cleveland K. A., Smith R. J. Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. Journal of Biological Chemistry. 2003;278(34):31564–31573. doi: 10.1074/jbc.M211572200.
    1. Smith P. D., Crocker S. J., Jackson-Lewis V., et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(23):13650–13655. doi: 10.1073/pnas.2232515100.
    1. Strauss K. M., Martins L. M., Plun-Favreau H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Human Molecular Genetics. 2005;14(15):2099–2111. doi: 10.1093/hmg/ddi215.
    1. Simón-Sánchez J., Schulte C., Bras J. M., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics. 2009;41(12):1308–1312. doi: 10.1038/ng.487.
    1. Chartier-Harlin M.-C., Dachsel J. C., Vilariño-Güell C., et al. Translation initiator EIF4G1 mutations in familial parkinson disease. The American Journal of Human Genetics. 2011;89(3):398–406. doi: 10.1016/j.ajhg.2011.08.009.
    1. Ostrerova N., Petrucelli L., Farrer M., et al. α-Synuclein shares physical and functional homology with 14-3-3 proteins. Journal of Neuroscience. 1999;19(14):5782–5791.
    1. Zhang Y., Sun Q.-Y., Yu R.-H., Guo J.-F., Tang B.-S., Yan X.-X. The contribution of GIGYF2 to Parkinson’s disease: a meta-analysis. Neurological Sciences. 2015;36(11):2073–2079. doi: 10.1007/s10072-015-2316-9.
    1. Spillantini M. G., Schmidt M. L., Lee V. M.-Y., Trojanowski J. Q., Jakes R., Goedert M. α-synuclein in Lewy bodies [8] Nature. 1997;388:839–840. doi: 10.1038/42166.
    1. Outeiro T. F., Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science. 2003;302(5651):1772–1775. doi: 10.1126/science.1090439.
    1. Cookson M. R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Reviews Neuroscience. 2010;11(12):791–797. doi: 10.1038/nrn2935.
    1. Plun-Favreau H., Klupsch K., Moisoi N., et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nature Cell Biology. 2007;9(11):1243–1252. doi: 10.1038/ncb1644.
    1. Clark I. E., Dodson M. W., Jiang C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin . Nature. 2006;441(7097):1162–1166. doi: 10.1038/nature04779.
    1. Schapira A. H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. The Lancet Neurology. 2008;7(1):97–109. doi: 10.1016/S1474-4422(07)70327-7.
    1. Lücking C. B., Dürr A., Bonifati V., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. New England Journal of Medicine. 2000;342(21):1560–1567. doi: 10.1056/NEJM200005253422103.
    1. Chung K. K. K., Zhang Y., Lim K. L., et al. Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine. 2001;7(10):1144–1150. doi: 10.1038/nm1001-1144.
    1. Bonifati V., Rizzu P., Van Baren M. J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256–259. doi: 10.1126/science.1077209.
    1. Abou-Sleiman P. M., Healy D. G., Quinn N., Lees A. J., Wood N. W. The role of pathogenic DJ-1 mutations in Parkinson's disease. Annals of Neurology. 2003;54(3):283–286. doi: 10.1002/ana.10675.
    1. Bandopadhyay R., Kingsbury A. E., Cookson M. R., et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain. 2004;127(2):420–430. doi: 10.1093/brain/awh054.
    1. Liu Z., Guo J., Wang Y., et al. Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson' s disease with cognitive impairment in a Chinese population. Scientific Reports. 2016;6 doi: 10.1038/srep19021.19021
    1. Wang Y. Q., Tang B. S., Yang Y., et al. Relationship between Alzheimer's disease GWAS-linked top hits and risk of Parkinson's disease with or without cognitive decline: a Chinese population-based study. Neurobiology of Aging. 2016;39:217.e9–217.e11. doi: 10.1016/j.neurobiolaging.2015.11.024.
    1. Okazaki H., Lipkin L. E., Aronson S. M. Diffuse intracytoplasmic ganglionic inclusions (lewy type) associated with progressive dementia and quadriparesis in flexion. Journal of Neuropathology and Experimental Neurology. 1961;20(2):237–244. doi: 10.1097/00005072-196104000-00007.
    1. Neumann J., Bras J., Deas E., et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132(7):1783–1794. doi: 10.1093/brain/awp044.
    1. Sidransky E., Nalls M. A., Aasly J. O., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine. 2009;361(17):1651–1661. doi: 10.1056/NEJMoa0901281.
    1. Guerini F. R., Beghi E., Riboldazzi G., et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. European Journal of Neurology. 2009;16(11):1240–1245. doi: 10.1111/j.1468-1331.2009.02706.x.
    1. Litvan I., Aarsland D., Adler C. H., et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Movement Disorders. 2011;26(10):1814–1824. doi: 10.1002/mds.23823.
    1. Wang Y.-Q., Tang B.-S., Yan X.-X., et al. A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China. Journal of Clinical Neuroscience. 2015;22(6):981–985. doi: 10.1016/j.jocn.2014.11.030.
    1. Muslimović D., Post B., Speelman J. D., Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–1245. doi: 10.1212/01.wnl.0000180516.69442.95.
    1. Foltynie T., Brayne C. E. G., Robbins T. W., Barker R. A. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN Study. Brain. 2004;127(3):550–560. doi: 10.1093/brain/awh067.
    1. Hoops S., Nazem S., Siderowf A. D., et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–1745. doi: 10.1212/WNL.0b013e3181c34b47.
    1. Mamikonyan E., Moberg P. J., Siderowf A., et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism and Related Disorders. 2009;15(3):226–231. doi: 10.1016/j.parkreldis.2008.05.006.
    1. Pai M.-C., Chan S.-H. Education and cognitive decline in parkinson's disease: a study of 102 patients. Acta Neurologica Scandinavica. 2001;103(4):243–247. doi: 10.1034/j.1600-0404.2001.103004243.x.
    1. Janvin C. C., Larsen J. P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Movement Disorders. 2006;21(9):1343–1349. doi: 10.1002/mds.20974.
    1. Williams-Gray C. H., Foltynie T., Brayne C. E. G., Robbins T. W., Barker R. A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130(7):1787–1798. doi: 10.1093/brain/awm111.
    1. Emre M., Aarsland D., Brown R., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders. 2007;22(12):1689–1707. doi: 10.1002/mds.21507.
    1. Dubois B., Burn D., Goetz C., et al. Diagnostic procedures for parkinson's disease dementia: recommendations from the movement disorder society task force. Movement Disorders. 2007;22(16):2314–2324. doi: 10.1002/mds.21844.
    1. Gibb W. R. G., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 1988;51(6):745–752. doi: 10.1136/jnnp.51.6.745.
    1. Hughes A. J., Daniel S. E., Blankson S., Lees A. J. A clinicopathologic study of 100 cases of Parkinson's disease. Archives of Neurology. 1993;50(2):140–148. doi: 10.1001/archneur.1993.00540020018011.
    1. Folstein M. F., Folstein S. E., McHugh P. R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Shum D. H. K., McFarland K. A., Bain J. D. Construct validity of eight tests of attention: comparison of normal and closed head injured samples. Clinical Neuropsychologist. 1990;4(2):151–162. doi: 10.1080/13854049008401508.
    1. Sunderland T., Hill J. L., Mellow A. M., et al. Clock drawing in Alzheimer's disease: a novel measure of dementia severity. Journal of the American Geriatrics Society. 1989;37(8):725–729. doi: 10.1111/j.1532-5415.1989.tb02233.x.
    1. Jacobson N. S., Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology. 1991;59(1):12–19. doi: 10.1037//0022-006x.59.1.12.
    1. Pillon B., Deweer B., Agid Y., Dubois B. Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Archives of Neurology. 1993;50(4):374–379. doi: 10.1001/archneur.1993.00540040036010.
    1. Weintraub D., Oehlberg K. A., Katz I. R., Stern M. B. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. The American Journal of Geriatric Psychiatry. 2006;14(2):169–175. doi: 10.1097/01.jgp.0000192488.66049.4b.
    1. Owen A. M., Beksinska M., James M., et al. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia. 1993;31(7):627–644. doi: 10.1016/0028-3932(93)90135-M.
    1. Cooper J. A., Sagar H. J., Jordan N., Harvey N. S., Sullivan E. V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991;114(5):2095–2122. doi: 10.1093/brain/114.5.2095.
    1. Flowers K. A., Robertson C. The effect of Parkinson's disease on the ability to maintain a mental set. Journal of Neurology Neurosurgery and Psychiatry. 1985;48(6):517–529. doi: 10.1136/jnnp.48.6.517.
    1. Lhermitte F., Pillon B., Serdaru M. Human autonomy and the frontal lobes. Part I: imitation and utilization behavior: a neuropsychological study of 75 patients. Annals of Neurology. 1986;19(4):326–334. doi: 10.1002/ana.410190404.
    1. Starkstein S. E., Mayberg H. S., Preziosi T. J., Andrezejewski P., Leiguarda R., Robinson R. G. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences. 1992;4(2):134–139. doi: 10.1176/jnp.4.2.134.
    1. Cummings J. L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D. A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314. doi: 10.1212/wnl.44.12.2308.
    1. Grober E., Buschke H. Genuine memory deficits in dementia. Developmental Neuropsychology. 1987;3(1):13–36. doi: 10.1080/87565648709540361.
    1. Tierney M. C., Nores A., Snow W. G., Fisher R. H., Zorzitto M. L., Reid D. W. Use of the Rey Auditory Verbal Learning Test in differentiating normal aging from Alzheimer's and Parkinson's dementia. Psychological Assessment. 1994;6(2):129–134. doi: 10.1037//1040-3590.6.2.129.
    1. Mosimann U. P., Mather G., Wesnes K. A., O'Brien J. T., Burn D. J., McKeith I. G. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63(11):2091–2096. doi: 10.1212/01.WNL.0000145764.70698.4E.
    1. Janvin C., Aarsland D., Larsen J. P., Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dementia and Geriatric Cognitive Disorders. 2003;15(3):126–131. doi: 10.1159/000068483.
    1. Benton A. L., Eslinger P. J., Damasio A. R. Normative observations on neuropsychological test performances in old age. Journal of Clinical Neuropsychology. 1981;3(1):33–42. doi: 10.1080/01688638108403111.
    1. Aarsland D., Brønnick K., Ehrt U., et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. Journal of Neurology, Neurosurgery and Psychiatry. 2007;78(1):36–42. doi: 10.1136/jnnp.2005.083113.
    1. Leentjens A. F. G., Verhey F. R. J., Lousberg R., Spitsbergen H., Wilmink F. W. The validity of the Hamilton and Montgomery-Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. International Journal of Geriatric Psychiatry. 2000;15(7):644–649. doi: 10.1002/1099-1166(200007)15:7<644::aid-gps167>;2-l.
    1. Visser M., Leentjens A. F. G., Marinus J., Stiggelbout A. M., van Hilten J. J. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Movement Disorders. 2006;21(5):668–672. doi: 10.1002/mds.20792.
    1. Ertan F. S., Ertan T., Kiziltan G., Uyguçgil H. Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2005;76(10):1445–1447. doi: 10.1136/jnnp.2004.057984.
    1. Brandstaedter D., Spieker S., Ulm G., et al. Development and evaluation of the Parkinson Psychosis Questionnaire: a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. Journal of Neurology. 2005;252(9):1060–1066. doi: 10.1007/s00415-005-0816-x.
    1. Kehagia A. A., Barker R. A., Robbins T. W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. The Lancet Neurology. 2010;9(12):1200–1213. doi: 10.1016/S1474-4422(10)70212-X.
    1. Klein J. C., Eggers C., Kalbe E., et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885–892. doi: 10.1212/WNL.0b013e3181d55f61.
    1. Rolinski M., Fox C., Maidment I., McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews. 2012;3CD006504
    1. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. The New England Journal of Medicine. 2004;351(24):2509–2518. doi: 10.1056/nejmoa041470.
    1. Poewe W., Wolters E., Emre M., et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's Disease: an active treatment extension study. Movement Disorders. 2006;21(4):456–461. doi: 10.1002/mds.20700.
    1. McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. The Lancet. 2000;356(9247):2031–2036. doi: 10.1016/s0140-6736(00)03399-7.
    1. Van Laar T., De Deyn P. P., Aarsland D., Barone P., Galvin J. E. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neuroscience and Therapeutics. 2011;17(5):428–441. doi: 10.1111/j.1755-5949.2010.00166.x.
    1. Dubois B., Tolosa E., Kulisevsky J., Barone P., Galvin E. J. Efficacy and safety of donepezil in the treatment of Parkinsons disease patients with dementia. Proceedings of the 8th International Conference on Alzheimers and Parkinsons Diseases; 2007.
    1. Leroi I., Overshott R., Byrne E. J., Daniel E., Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders. 2009;24(8):1217–1221. doi: 10.1002/mds.22495.
    1. Aarsland D., Ballard C., Walker Z., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology. 2009;8(7):613–618. doi: 10.1016/S1474-4422(09)70146-2.
    1. Emre M., Tsolaki M., Bonuccelli U., et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2010;9(10):969–977. doi: 10.1016/s1474-4422(10)70194-0.
    1. Ondo W. G., Shinawi L., Davidson A., Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders. 2011;17(3):156–159. doi: 10.1016/j.parkreldis.2010.12.003.
    1. Larsson V., Engedal K., Aarsland D., Wattmo C., Minthon L., Londos E. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson's disease dementia. Dementia and Geriatric Cognitive Disorders. 2011;32(4):227–234. doi: 10.1159/000334523.
    1. Seppi K., Weintraub D., Coelho M., et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders. 2011;26, supplement 3:S42–S80. doi: 10.1002/mds.23884.
    1. Cooper J. A., Sagar H. J., Doherty S. M., Jordan N., Tidswell P., Sullivan E. V. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease follow-up study of untreated patients. Brain. 1992;115(6):1701–1725. doi: 10.1093/brain/115.6.1701.
    1. Inzelberg R., Bonuccelli U., Schechtman E., et al. Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders. 2006;21(9):1375–1379. doi: 10.1002/mds.20968.
    1. Witt K., Daniels C., Krack P., et al. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease. Journal of the Neurological Sciences. 2011;310(1-2):261–266. doi: 10.1016/j.jns.2011.06.028.
    1. Daniels C., Krack P., Volkmann J., et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Movement Disorders. 2010;25(11):1583–1589. doi: 10.1002/mds.23078.
    1. Bäckman L., Nyberg L., Soveri A., et al. Effects of working-memory training on striatal dopamine release. Science. 2011;333(6043) doi: 10.1126/science.1204978.
    1. Tang V., Zhu C. X. L., Chan D., et al. Evidence of improved immediate verbal memory and diminished category fluency following STN-DBS in Chinese-Cantonese patients with idiopathic Parkinson's disease. Neurological Sciences. 2015;36(8):1371–1377. doi: 10.1007/s10072-015-2117-1.
    1. Abboud H., Floden D., Thompson N. R., et al. Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease. Parkinsonism and Related Disorders. 2015;21(3):249–253. doi: 10.1016/j.parkreldis.2014.12.018.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe